Novel therapies in clinical development in AML
| Novel therapies in clinical development . | |
|---|---|
| Protein kinase inhibitors | • FLT3 inhibitors (midostaurin, quizartinib, gilteritinib, crenolanib) |
| • KIT inhibitors | |
| • PI3K/AKT/mTOR inhibitors | |
| • Aurora and polo-like kinase inhibitors, CDK4/6 inhibitors, CHK1, WEE1, and MPS1 inhibitors | |
| • SRC and HCK inhibitors | |
| Epigenetic modulators | • New DNA methyltransferase inhibitors (SGI-110) |
| • HDAC inhibitors | |
| • IDH1 and IDH2 inhibitors | |
| • DOT1L inhibitors | |
| • BET-bromodomain inhibitors | |
| Chemotherapeutic agents | • CPX-351 |
| • Vosaroxin | |
| • Nucleoside analogs | |
| Mitochondrial inhibitors | • Bcl-2, Bcl-xL, and Mcl-1 inhibitors |
| • Caseinolytic protease inhibitors | |
| Therapies targeting oncogenic proteins | • Fusion transcripts targeting |
| • EVI1 targeting | |
| • NPM1 targeting | |
| • Hedgehog inhibitors | |
| Antibodies and immunotherapies | • Monoclonal antibodies against CD33, CD44, CD47, CD123, CLEC12A |
| • Immunoconjugates (eg, GO, SGN33A) | |
| • BiTEs and DARTs | |
| • CAR T cells or genetically engineered TCR T cells | |
| • Immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4) | |
| • Anti-KIR antibody | |
| • Vaccines (eg, WT1) | |
| Therapies targeting AML environment | • CXCR4 and CXCL12 antagonists |
| • Antiangiogenic therapies | |
| Novel therapies in clinical development . | |
|---|---|
| Protein kinase inhibitors | • FLT3 inhibitors (midostaurin, quizartinib, gilteritinib, crenolanib) |
| • KIT inhibitors | |
| • PI3K/AKT/mTOR inhibitors | |
| • Aurora and polo-like kinase inhibitors, CDK4/6 inhibitors, CHK1, WEE1, and MPS1 inhibitors | |
| • SRC and HCK inhibitors | |
| Epigenetic modulators | • New DNA methyltransferase inhibitors (SGI-110) |
| • HDAC inhibitors | |
| • IDH1 and IDH2 inhibitors | |
| • DOT1L inhibitors | |
| • BET-bromodomain inhibitors | |
| Chemotherapeutic agents | • CPX-351 |
| • Vosaroxin | |
| • Nucleoside analogs | |
| Mitochondrial inhibitors | • Bcl-2, Bcl-xL, and Mcl-1 inhibitors |
| • Caseinolytic protease inhibitors | |
| Therapies targeting oncogenic proteins | • Fusion transcripts targeting |
| • EVI1 targeting | |
| • NPM1 targeting | |
| • Hedgehog inhibitors | |
| Antibodies and immunotherapies | • Monoclonal antibodies against CD33, CD44, CD47, CD123, CLEC12A |
| • Immunoconjugates (eg, GO, SGN33A) | |
| • BiTEs and DARTs | |
| • CAR T cells or genetically engineered TCR T cells | |
| • Immune checkpoint inhibitors (PD-1/PD-L1, CTLA-4) | |
| • Anti-KIR antibody | |
| • Vaccines (eg, WT1) | |
| Therapies targeting AML environment | • CXCR4 and CXCL12 antagonists |
| • Antiangiogenic therapies | |
BiTE, bispecific T-cell engager; CAR, chimeric antigen receptor; DART, dual-affinity retargeting molecule; HDAC, histone deacetylase; KIR, killer-cell immunoglobulin-like receptor; mTOR, mechanistic target of rapamycin; PD-1, programmed cell death protein 1; PD-L1, programmed death ligand 1; PI3K, phosphatidylinositol 3-kinase; TCR, T-cell receptor.